NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled
NCT05887492 2025-11-18Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting126 enrolled
NCT03184571 2025-09-25Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)BerGenBio ASAPhase 2 Completed99 enrolled 20 charts
NCT04682431 2024-03-22A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated127 enrolled
NCT04691375 2024-03-22A Study of PY314 in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated86 enrolled
NCT04452214 2023-07-14A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCantargia ABPhase 1 Completed19 enrolled